Pharvaris (Nasdaq: PHVS) presented a summary of clinical data supporting deucrictibant's differentiated therapeutic profile at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, held June 12–15 in Istanbul, Turkey. The oral bradykinin B2 receptor antagonist is under development for hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), conditions characterized by episodic, potentially life-threatening swelling driven by dysregulated bradykinin signaling.
Deucrictibant works by selectively blocking the bradykinin B2 receptor, the key mediator of vascular permeability and edema formation in bradykinin-mediated angioedema. Unlike injectable kallikrein inhibitors that dominate the current standard of care, deucrictibant is designed for oral delivery — a formulation distinction that carries meaningful implications for patient compliance and long-term prophylactic use. Pharvaris has not released new top-line efficacy numbers from EAACI beyond previously disclosed clinical endpoints from its CHAPTER and PARACHUTE trial programs.
HAE is an ultra-rare genetic disorder affecting an estimated 1 in 50,000 individuals globally, yet the treatment market commands significant commercial value given the severity of attacks and chronic prophylaxis requirements. The broader plasma kallikrein–kinin system inhibitor class has attracted substantial investment, with several biologic and small-molecule entrants competing on dosing convenience, onset of action, and route of administration. An orally bioavailable option that demonstrates comparable clinical endpoints to injectable standards could address a persistent unmet need among patients seeking less burdensome long-term management.
For operators in the nutraceutical and functional food space tracking adjacencies in bradykinin biology — including emerging interest in ACE-inhibitory peptides and botanical extracts with proposed kinin-modulating activity — the clinical progress of targeted B2 receptor antagonists like deucrictibant offers a useful mechanistic benchmark. The rigorous double-blind, placebo-controlled trial infrastructure Pharvaris is deploying also underscores the evidentiary bar that condition-specific structure-function claims in the supplement channel increasingly face from regulators and retailers alike.
Pharvaris is headquartered in Zug, Switzerland, and is advancing deucrictibant through late-stage development. The company has not announced a regulatory filing timeline or commercialization partnership as of the EAACI presentation date. Further data disclosures are anticipated as the CHAPTER-KIDS pediatric program and on-demand treatment studies progress.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.